

generation platinum drug designed to have an extended spectrum of anti-tumour activity and overcome platinum resistance mechanisms, has shown synergistic in vitro activity in combination with paclitaxel. The purpose of this ongoing Phase I trial is to evaluate the safety of ZD0473 in combination with paclitaxel, in patients with refractory solid malignancies.

Methods: Patients received a 3-hour iv infusion of paclitaxel, followed after 30 min by a 1-hour infusion of ZD0473, repeated every 3 weeks.

Results: To date, 17 patients (NSCLC [12 patients], mesothelioma [3], SCLC [2]) have been recruited and have received paclitaxel/ZD0473 combinations at doses of 135/60, 135/90, 135/120, 150/120, or 175/120 mg/m². The median (range) of treatment cycles received to date is 3 (1-6), with 8 patients having received at least 4 cycles of treatment. During the first treatment cycle myelosuppression was mild: 1 patient had grade 3/4 anaemia; there were no incidences of grade 3/4 thrombocytopenia or neutropenia. Nine patients were withdrawn due to disease progression. So far, no patients have experienced dose-limiting toxicity. Stable disease was observed in 9 of the 13 evaluable patients, including 3 patients with NSCLC who experienced a reduction in tumour size of ~10%. The median number of treatment cycles received by patients with stable disease was 4 (range 2-6).

Conclusion: The ZD0473 and paclitaxel combination is well tolerated and shows encouraging stable disease in patients with solid tumours.

265

POSTER

A phase I study of weekly Oxaliplatin (OXA) + continuous infusion (CI) fluorouracil (FU) in patients with advanced colorectal cancer (CCR)

A. Aschele, S. Lonardi, L. Sartor, A. Perin, V. Chiarion Sileni, G. Artioli, S. Monfardini. *Padova University Hospital, Medical Oncology, Padova, Italy*

A combination of OXA and FU is frequently used as 1st or 2nd line treatment for advanced CCR. However, the optimal schedule for this combination has not been defined. Weekly administration of OXA may result in decreased acute toxicity and increased dose intensity compared to bi- or tri-weekly administration. The purpose of this study was thus to identify the MTD of weekly OXA (4 dose levels: 60-70-80-90 mg/m² on days 1, 8, 15) in combination with a fixed daily dose of CI FU (200mg/m²/die d1a21) + Leucovorin (LV), with cycles repeated every 4 weeks. Since April 2000, 20 patients with progressive advanced CCR, previously treated with or ineligible for 5-FU and CPT-11 were accrued (13 males, 7 females; median age 68 years; median ECOG PS 1; median CEA 31.5 ng/ml).

Overall, 56 cycles were delivered corresponding to 163 weeks of chemotherapy. The median number of cycles administered to each patient was 2 (range 1-6) and the median number of weeks of chemotherapy was 6 (range 3-18). Fifteen of 163 weeks of chemotherapy were delayed because of toxicity while 6 of 163 weeks were delivered at a reduced dose. Considering the first 2 cycles of treatment (2 months), no grade III-IV toxicity was observed up to dose level 4 (OXA 90 mg/m²). Three patients presented grade I thrombocytopenia lasting 19, 14 and 14 days, respectively. Three out of 6 patients treated at dose level 4 (OXA 90 mg/m²) required a major change in the treatment program (discontinuation, delay longer than 14 days or dose reduction) because of constitutional symptoms (asthenia, weight loss and unbearable peripheral sensory neuropathy). This was thus deemed to be the MTD for OXA in this combination. Among 15 patients with measurable disease completing at least one treatment cycle 1 PR, 4 MR, 7 SD and 3 P were obtained. Overall, disease progression was abrogated in 12 of 18 evaluable patients. Three patients with initially unresectable liver metastases underwent secondary resection with curative intent.

These results demonstrate that the combination of weekly OXA and low-dose CI FU is feasible and well tolerated. This regimen allows to deliver a higher dose intensity of OXA compared to bi-weekly or tri-weekly schedules and shows a promising antitumor activity in heavily pretreated patients. The study is now continuing to assess the possibility of incorporating LV (20 mg/m², d1, 8, 15) at the OXA dose level below the MTD (80 mg/m²).

266

POSTER

A phase I, dose-escalation study of the novel antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

J.P. Stevenson¹, K. Algazy¹, K. McLaughlin¹, D.G. Haller¹, B.J. Giantonio¹, M. Koehler¹, J.E. Garcia-Vargas², P.J. O'Dwyer¹.

¹ University of Pennsylvania Cancer Center, Philadelphia, USA;

² AstraZeneca, Wilmington, USA

Introduction: ZD9331 is a new antifolate cytotoxic that inhibits thymidylate synthase and does not require polyglutamation for its activity.

Objectives: To determine the maximum tolerated dose (MTD) for ZD9331 in combination with cisplatin and to assess the tolerability, pharmacokinetic and antitumor activity of the combination.

Methods: Thirteen patients with refractory solid tumors have been entered to date. ZD9331 was administered as a 30-min iv infusion on days 1 and 8 of a 21-day cycle. Cisplatin was administered after ZD9331 as a 30- to 60-min infusion on day 1. The MTD was defined as that which caused dose-limiting toxicity (DLT) in ~2/6 patients.

Results: Patients entered on one of three dose levels: ZD9331/cisplatin 100/50 (n=3), 130/50 (n=6) and 130/75 (n=4) mg/m². Baseline performance status (PS) was good (PS 0 in 3 patients, PS 1 in 10 patients), and most patients had received prior chemotherapy. The majority of patients had thoracic malignancies. DLT was observed in 2 patients at 130/75. Both had grade 3/4 neutropenia requiring the day 8 dose of ZD9331 to be withheld. A third patient at this dose level experienced similar toxicity on his second cycle of treatment. Other toxicities include thrombocytopenia, anemia, fatigue, nausea, vomiting, and stomatitis. Accrual to the 130/50 dose level continues. Of the 13 patients entered, there has been 1 partial response in a patient with mesothelioma. Patients with mesothelioma and breast cancer also have stable disease.

Conclusions: The combination of ZD9331 and cisplatin is well tolerated and has antitumor activity.

267

POSTER

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours

N. Androulakis, Ch. Kouroussis, D. Mavroudis, S. Agelaki, J. Souglakos, N. Vardakis, A. Pallas, V. Bozionelou, V. Georgoulas. *Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece*

Objectives: Paclitaxel has a broad spectrum of toxicity against the most common human tumours. Weekly administration of paclitaxel may improve the toxicity profile of the drug increasing its efficacy. Liposomal doxorubicin (Caelyx) has shown similar to conventional doxorubicin's activity with much more favorable toxicity profile. A phase I study was conducted to determine the maximum tolerate dose (MTD) and the dose limiting toxicities (DLTs) of the combination of the two drugs administered weekly in patients with advanced solid tumours.

Patients and Methods: Escalating doses of Caelyx (6-12 mg/m²) were administered as a 1 h IV infusion and a fixed dose (80 mg/m²) of paclitaxel as a 3 h IV infusion on the same day for 4 consecutive weeks in a 6 week cycle. Nineteen previously treated patients with histologically confirmed advanced stage solid tumours were enrolled.

Results: The MTD was reached at the dose-level Caelyx 10 mg/m² + paclitaxel 80 mg/m². The DLTs were evaluated after the first cycle and consisted in all cases of grade 3 neutropenia resulting in treatment delay. A total of 55 cycles have been administered: Grade 2-3 neutropenia was observed in 7 (14%) cycles and grade 4 anemia in 1 (2%) cycle. Non hematologic toxicity included grade 2-3 nausea-vomiting in 5 (9%), grade 2-3 diarrhea in 4 (7.2%), grade 2-4 fatigue in 7 (12.7%) and grade 2 mucositis in 1 (1.8%) of the cycles. No cardiotoxicity, as determined by the development of CHF or more than 10% reduction on LVEF was observed. Among 12 evaluable patients, 1 PR was observed in a patient with ovarian cancer.

268

POSTER

A phase I study of the caelyx - Oxaliplatin combination in patients with advanced solid tumors

D. Mavroudis, Ch. Kouroussis, S. Kakolyris, J. Souglakos, N. Vardakis, N. Androulakis, G. Samonis, V. Georgoulas. *University General Hospital of Heraklion, Department of Medical Oncology, Crete, Greece*

Background: Caelyx is a liposomal doxorubicin formulation with low toxicity and high activity in various tumors. Oxaliplatin (L-OHP) is a new platinum analog with improved toxicity profile and only partial cross resistance with cisplatin and carboplatin. We conducted a phase I study to evaluate the MTD and DLT of the Caelyx-L-OHP combination.

Patients and Treatment: Caelyx was administered on day 1 as an 1-hour IV infusion at escalating doses of 25-35 mg/m², followed by L-OHP as a 2-hour IV infusion at doses of 80-100 mg/m². Cycles were repeated every 3 weeks without growth factors. Eighteen patients with advanced stage carcinomas have been entered. Median age 60, PS (WHO) 0.6: 1.9: 2.3. Treatment was 1st line for 5 (28%), 2nd line for 7 (39%) and 3rd line for 6 (33%) pts. DLT was evaluated during the first cycle of treatment and included any grade 4 hematologic toxicity, neutropenia grade 3-4 with